Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ventyx Biosciences Inc. operates a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company's current prosecution landscape includes 1 pending office action reported. This activity is confined to 1 distinct art unit, suggesting that the company's current legal focus is limited to a specific niche within the broader biotechnology sector. Such a narrow distribution indicates that the company is not currently managing a high volume of simultaneous disputes or applications.
The portfolio is currently being reviewed by 1 distinct examiner, which centralizes the examination process. DEKARSKE, MADELINE MCGUIRE is the busiest examiner assigned to the portfolio, currently managing 1 pending office action. Since the total number of pending actions matches the count assigned to DEKARSKE, MADELINE MCGUIRE, there is no distribution of work across multiple examiners. This concentration allows for a focused approach to the requirements and preferences of the examiner within 1 distinct art unit, simplifying the administrative tracking of the company's patent applications. Practitioners should note that the progress of the portfolio is currently tied to the specific examination style of this individual within the 1 distinct art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEKARSKE, MADELINE MCGUIRE | 1 | 20.0% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18347479 | CRYSTALLINE FORMS OF A TYK2 INHIBITOR | DEKARSKE, MADELINE MCGUIRE | 46d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18347479 | CRYSTALLINE FORMS OF A TYK2 INHIBITOR | DEKARSKE, MADELINE MCGUIRE | 46d |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18347479 | CRYSTALLINE FORMS OF A TYK2 INHIBITOR | DEKARSKE, MADELINE MCGUIRE | 1622 | §102§103Other | Non-Final OA | 46d | Pending | Jul 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVentyx Biosciences Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Madeline Mcguire Dekarske has the most, with 1 of Ventyx Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.